Finastéride oral 1 mg face à Dutastéride oral 0,1 mg

Adjusted meanHGItotalscoresatweek24were significantly higher in the dutasteride 0.1 mg (2.8), dutasteride0.5mg(3.2),andfinasteride(2.5)groups versus placebo (1.1; all P \ .001); there was no significant difference between adjusted mean HGI total scores in the dutasteride 0.02 mg (1.1) and placebo(1.1;P=.80)groups.

Gubelin Harcha W, Barboza Martínez J, Tsai TF et al.. A randomized, active- and placebo-controlled study of the efficacy and safety of different doses of dutasteride versus placebo and finasteride in the treatment of male subjects with androgenetic alopecia.. J Am Acad Dermatol 2014, DOI 10.1016/j.jaad.2013.10.049. Citation reproduite au titre du droit de courte citation (article L122-5 du Code de la propriété intellectuelle).

Adjusted meanHGItotalscoresatweek24were significantly higher in the dutasteride 0.1 mg (2.8), dutasteride0.5mg(3.2),andfinasteride(2.5)groups versus placebo (1.1; all P \ .001); there was no significant difference between adjusted mean HGI total scores in the dutasteride 0.02 mg (1.1) and placebo(1.1;P=.80)groups.

Gubelin Harcha W, Barboza Martínez J, Tsai TF et al.. A randomized, active- and placebo-controlled study of the efficacy and safety of different doses of dutasteride versus placebo and finasteride in the treatment of male subjects with androgenetic alopecia.. J Am Acad Dermatol 2014, DOI 10.1016/j.jaad.2013.10.049. Citation reproduite au titre du droit de courte citation (article L122-5 du Code de la propriété intellectuelle).

Hair count (2.54-cm diameter). The increase inbaselinehaircountwassuperiorinthedutasteride 0.1,dutasteride0.5mg,andfinasteridegroupsversus placebo at week 24 (all P \ .001) (Fig 2, A).

Gubelin Harcha W, Barboza Martínez J, Tsai TF et al.. A randomized, active- and placebo-controlled study of the efficacy and safety of different doses of dutasteride versus placebo and finasteride in the treatment of male subjects with androgenetic alopecia.. J Am Acad Dermatol 2014, DOI 10.1016/j.jaad.2013.10.049. Citation reproduite au titre du droit de courte citation (article L122-5 du Code de la propriété intellectuelle).

Hair count (2.54-cm diameter). The increase inbaselinehaircountwassuperiorinthedutasteride 0.1,dutasteride0.5mg,andfinasteridegroupsversus placebo at week 24 (all P \ .001) (Fig 2, A).

Gubelin Harcha W, Barboza Martínez J, Tsai TF et al.. A randomized, active- and placebo-controlled study of the efficacy and safety of different doses of dutasteride versus placebo and finasteride in the treatment of male subjects with androgenetic alopecia.. J Am Acad Dermatol 2014, DOI 10.1016/j.jaad.2013.10.049. Citation reproduite au titre du droit de courte citation (article L122-5 du Code de la propriété intellectuelle).

Terminal hair count. Adjusted mean change from baseline in terminal hair count (2.54-cm 6 Gubelin Harcha et al Fig 3. Adjusted mean change from baseline in JAMACADDERMATOL target area (2.54-cm diameter) hair width ((cid:1)m31e-3)atweek24forplacebo,dutasteride0.02to0.5mg,andfinasteride1mg.*P\.001 vsplacebo;yP=.004vsfinasteride(superiority). Fig4. Medianscoresforpanelglobalphotographicassessmentofimprovementofhairgrowth at the vertex and frontal/superior views at week 24. *P \.001 vs placebo; yP = .002 vs finasteride(superiority). diameter) at week 24 was superior in the dutaster- ide 0.1 and 0.5 mg (29.4 and 46.0 hairs) and finasteride (36.3 hairs) groups versus placebo ((cid:1)17.5 hairs; all P \ .001); dutasteride 0.02 mg was not superior to placebo ((cid:1)15.7 hairs, P = .81). Dutasteride 0.1 and 0.5 mg were not superior to finasterideatincreasingterminalhaircountatweek 24 (P = .34 and P = .19).

Gubelin Harcha W, Barboza Martínez J, Tsai TF et al.. A randomized, active- and placebo-controlled study of the efficacy and safety of different doses of dutasteride versus placebo and finasteride in the treatment of male subjects with androgenetic alopecia.. J Am Acad Dermatol 2014, DOI 10.1016/j.jaad.2013.10.049. Citation reproduite au titre du droit de courte citation (article L122-5 du Code de la propriété intellectuelle).

Terminal hair count. Adjusted mean change from baseline in terminal hair count (2.54-cm 6 Gubelin Harcha et al Fig 3. Adjusted mean change from baseline in JAMACADDERMATOL target area (2.54-cm diameter) hair width ((cid:1)m31e-3)atweek24forplacebo,dutasteride0.02to0.5mg,andfinasteride1mg.*P\.001 vsplacebo;yP=.004vsfinasteride(superiority). Fig4. Medianscoresforpanelglobalphotographicassessmentofimprovementofhairgrowth at the vertex and frontal/superior views at week 24. *P \.001 vs placebo; yP = .002 vs finasteride(superiority). diameter) at week 24 was superior in the dutaster- ide 0.1 and 0.5 mg (29.4 and 46.0 hairs) and finasteride (36.3 hairs) groups versus placebo ((cid:1)17.5 hairs; all P \ .001); dutasteride 0.02 mg was not superior to placebo ((cid:1)15.7 hairs, P = .81). Dutasteride 0.1 and 0.5 mg were not superior to finasterideatincreasingterminalhaircountatweek 24 (P = .34 and P = .19).

Gubelin Harcha W, Barboza Martínez J, Tsai TF et al.. A randomized, active- and placebo-controlled study of the efficacy and safety of different doses of dutasteride versus placebo and finasteride in the treatment of male subjects with androgenetic alopecia.. J Am Acad Dermatol 2014, DOI 10.1016/j.jaad.2013.10.049. Citation reproduite au titre du droit de courte citation (article L122-5 du Code de la propriété intellectuelle).

Hair count (1.13-cm diameter). All active treatment groups except dutasteride 0.02 mg were superiortoplaceboinincreasinghaircountatweek 24 (all P \ .001) (Fig 2, B). Dutasteride 0.5 mg JAMACADDERMATOL Gubelin Harcha etal 5 Fig2. A,Adjustedmeanchangefrombaselineintargetareahaircount(2.54cm)atweeks12and24 forplacebo,dutasteride 0.02 to 0.5mg,and finasteride 1mg.*P= .009,yP\.001 vsplacebo; znoninferiortofinasteride;xP=.003vsfinasteride(superiority).B,Adjustedmeanchangefrom baselineintargetareahaircount(1.13cm)atweeks12and24forplacebo,dutasteride0.02to0.5mg, andfinasteride1mg.*P=.015,yP\.001vsplacebo;xP=.008,**P=.016vsfinasteride(superiority). significantly increased hair count versus finasteride atweek24(P=.016).

Gubelin Harcha W, Barboza Martínez J, Tsai TF et al.. A randomized, active- and placebo-controlled study of the efficacy and safety of different doses of dutasteride versus placebo and finasteride in the treatment of male subjects with androgenetic alopecia.. J Am Acad Dermatol 2014, DOI 10.1016/j.jaad.2013.10.049. Citation reproduite au titre du droit de courte citation (article L122-5 du Code de la propriété intellectuelle).

Hair count (1.13-cm diameter). All active treatment groups except dutasteride 0.02 mg were superiortoplaceboinincreasinghaircountatweek 24 (all P \ .001) (Fig 2, B). Dutasteride 0.5 mg JAMACADDERMATOL Gubelin Harcha etal 5 Fig2. A,Adjustedmeanchangefrombaselineintargetareahaircount(2.54cm)atweeks12and24 forplacebo,dutasteride 0.02 to 0.5mg,and finasteride 1mg.*P= .009,yP\.001 vsplacebo; znoninferiortofinasteride;xP=.003vsfinasteride(superiority).B,Adjustedmeanchangefrom baselineintargetareahaircount(1.13cm)atweeks12and24forplacebo,dutasteride0.02to0.5mg, andfinasteride1mg.*P=.015,yP\.001vsplacebo;xP=.008,**P=.016vsfinasteride(superiority). significantly increased hair count versus finasteride atweek24(P=.016).

Gubelin Harcha W, Barboza Martínez J, Tsai TF et al.. A randomized, active- and placebo-controlled study of the efficacy and safety of different doses of dutasteride versus placebo and finasteride in the treatment of male subjects with androgenetic alopecia.. J Am Acad Dermatol 2014, DOI 10.1016/j.jaad.2013.10.049. Citation reproduite au titre du droit de courte citation (article L122-5 du Code de la propriété intellectuelle).

Hair width. Dutasteride0.1,dutasteride0.5mg, and finasteride were superior to placebo at increasing hair width (2.54-cm diameter) versus placebo at week 24 (all P \ .001) (Fig 3); only dutasteride0.5mgsignificantlyincreasedhairwidth versusfinasterideatweek24(P=.004).

Gubelin Harcha W, Barboza Martínez J, Tsai TF et al.. A randomized, active- and placebo-controlled study of the efficacy and safety of different doses of dutasteride versus placebo and finasteride in the treatment of male subjects with androgenetic alopecia.. J Am Acad Dermatol 2014, DOI 10.1016/j.jaad.2013.10.049. Citation reproduite au titre du droit de courte citation (article L122-5 du Code de la propriété intellectuelle).

Hair width. Dutasteride0.1,dutasteride0.5mg, and finasteride were superior to placebo at increasing hair width (2.54-cm diameter) versus placebo at week 24 (all P \ .001) (Fig 3); only dutasteride0.5mgsignificantlyincreasedhairwidth versusfinasterideatweek24(P=.004).

Gubelin Harcha W, Barboza Martínez J, Tsai TF et al.. A randomized, active- and placebo-controlled study of the efficacy and safety of different doses of dutasteride versus placebo and finasteride in the treatment of male subjects with androgenetic alopecia.. J Am Acad Dermatol 2014, DOI 10.1016/j.jaad.2013.10.049. Citation reproduite au titre du droit de courte citation (article L122-5 du Code de la propriété intellectuelle).

Investigator assessment IPAQ scores at week 24 are shown in Table III (available at http://www.jaad.org). Compared with placebo, dutasteride 0.1, dutasteride 0.5 mg, and finasteride significantly improved hair growth (assessed by adjusted mean IPAQ scores) in the vertex(1.03,1.30,and1.07vs0.36,respectively)and frontal/superior views (0.78, 1.11, and 0.88 vs 0.30, respectively) at week 24 (all P\.001). Dutasteride was not superior to finasteride at improving hair growth in the vertex and frontal/superior views (assessedbymeanIPAQscores)atweek24.

Gubelin Harcha W, Barboza Martínez J, Tsai TF et al.. A randomized, active- and placebo-controlled study of the efficacy and safety of different doses of dutasteride versus placebo and finasteride in the treatment of male subjects with androgenetic alopecia.. J Am Acad Dermatol 2014, DOI 10.1016/j.jaad.2013.10.049. Citation reproduite au titre du droit de courte citation (article L122-5 du Code de la propriété intellectuelle).

Investigator assessment IPAQ scores at week 24 are shown in Table III (available at http://www.jaad.org). Compared with placebo, dutasteride 0.1, dutasteride 0.5 mg, and finasteride significantly improved hair growth (assessed by adjusted mean IPAQ scores) in the vertex(1.03,1.30,and1.07vs0.36,respectively)and frontal/superior views (0.78, 1.11, and 0.88 vs 0.30, respectively) at week 24 (all P\.001). Dutasteride was not superior to finasteride at improving hair growth in the vertex and frontal/superior views (assessedbymeanIPAQscores)atweek24.

Gubelin Harcha W, Barboza Martínez J, Tsai TF et al.. A randomized, active- and placebo-controlled study of the efficacy and safety of different doses of dutasteride versus placebo and finasteride in the treatment of male subjects with androgenetic alopecia.. J Am Acad Dermatol 2014, DOI 10.1016/j.jaad.2013.10.049. Citation reproduite au titre du droit de courte citation (article L122-5 du Code de la propriété intellectuelle).

Investigator assessment IPAQ scores at week 24 are shown in Table III (available at http://www.jaad.org). Compared with placebo, dutasteride 0.1, dutasteride 0.5 mg, and finasteride significantly improved hair growth (assessed by adjusted mean IPAQ scores) in the vertex(1.03,1.30,and1.07vs0.36,respectively)and frontal/superior views (0.78, 1.11, and 0.88 vs 0.30, respectively) at week 24 (all P\.001). Dutasteride was not superior to finasteride at improving hair growth in the vertex and frontal/superior views (assessedbymeanIPAQscores)atweek24.

Gubelin Harcha W, Barboza Martínez J, Tsai TF et al.. A randomized, active- and placebo-controlled study of the efficacy and safety of different doses of dutasteride versus placebo and finasteride in the treatment of male subjects with androgenetic alopecia.. J Am Acad Dermatol 2014, DOI 10.1016/j.jaad.2013.10.049. Citation reproduite au titre du droit de courte citation (article L122-5 du Code de la propriété intellectuelle).

Investigator assessment IPAQ scores at week 24 are shown in Table III (available at http://www.jaad.org). Compared with placebo, dutasteride 0.1, dutasteride 0.5 mg, and finasteride significantly improved hair growth (assessed by adjusted mean IPAQ scores) in the vertex(1.03,1.30,and1.07vs0.36,respectively)and frontal/superior views (0.78, 1.11, and 0.88 vs 0.30, respectively) at week 24 (all P\.001). Dutasteride was not superior to finasteride at improving hair growth in the vertex and frontal/superior views (assessedbymeanIPAQscores)atweek24.

Gubelin Harcha W, Barboza Martínez J, Tsai TF et al.. A randomized, active- and placebo-controlled study of the efficacy and safety of different doses of dutasteride versus placebo and finasteride in the treatment of male subjects with androgenetic alopecia.. J Am Acad Dermatol 2014, DOI 10.1016/j.jaad.2013.10.049. Citation reproduite au titre du droit de courte citation (article L122-5 du Code de la propriété intellectuelle).

TableV.Adverseevents,includingcommonadverseeventsreportedpostrandomizationbytreatmentgroup Placebo N=181 Dutasteride Finasteride 0.02mg 0.1mg 0.5mg 1mg N=185 N=188 N=184 N=179 n(%)[events] n(%)[events] n(%)[events] n(%)[events] n(%)[events] AnyAE 94(52)[185] 91 Anydrug-related AE 27(15)[40] 26

Citation complémentaire (valeur)

(49)[192] 95(51)[201] 100 (54)[217] 94(53)[189] (14)[48] 39(21)[52] 30(16)[41] 35(20)[48]

Gubelin Harcha W, Barboza Martínez J, Tsai TF et al.. A randomized, active- and placebo-controlled study of the efficacy and safety of different doses of dutasteride versus placebo and finasteride in the treatment of male subjects with androgenetic alopecia.. J Am Acad Dermatol 2014, DOI 10.1016/j.jaad.2013.10.049. Citation reproduite au titre du droit de courte citation (article L122-5 du Code de la propriété intellectuelle).

TableV.Adverseevents,includingcommonadverseeventsreportedpostrandomizationbytreatmentgroup Placebo N=181 Dutasteride Finasteride 0.02mg 0.1mg 0.5mg 1mg N=185 N=188 N=184 N=179 n(%)[events] n(%)[events] n(%)[events] n(%)[events] n(%)[events] AnyAE 94(52)[185] 91 Anydrug-related AE 27(15)[40] 26

Citation complémentaire (valeur)

(49)[192] 95(51)[201] 100 (54)[217] 94(53)[189] (14)[48] 39(21)[52] 30(16)[41] 35(20)[48]

Gubelin Harcha W, Barboza Martínez J, Tsai TF et al.. A randomized, active- and placebo-controlled study of the efficacy and safety of different doses of dutasteride versus placebo and finasteride in the treatment of male subjects with androgenetic alopecia.. J Am Acad Dermatol 2014, DOI 10.1016/j.jaad.2013.10.049. Citation reproduite au titre du droit de courte citation (article L122-5 du Code de la propriété intellectuelle).

TableV.Adverseevents,includingcommonadverseeventsreportedpostrandomizationbytreatmentgroup Placebo N=181 Dutasteride Finasteride 0.02mg 0.1mg 0.5mg 1mg N=185 N=188 N=184 N=179 n(%)[events] n(%)[events] n(%)[events] n(%)[events] n(%)[events] AnyAE 94(52)[185] 91 Anydrug-related AE 27(15)[40] 26

Citation complémentaire (valeur)

(49)[192] 95(51)[201] 100 (54)[217] 94(53)[189] (14)[48] 39(21)[52] 30(16)[41] 35(20)[48]

Gubelin Harcha W, Barboza Martínez J, Tsai TF et al.. A randomized, active- and placebo-controlled study of the efficacy and safety of different doses of dutasteride versus placebo and finasteride in the treatment of male subjects with androgenetic alopecia.. J Am Acad Dermatol 2014, DOI 10.1016/j.jaad.2013.10.049. Citation reproduite au titre du droit de courte citation (article L122-5 du Code de la propriété intellectuelle).

TableV.Adverseevents,includingcommonadverseeventsreportedpostrandomizationbytreatmentgroup Placebo N=181 Dutasteride Finasteride 0.02mg 0.1mg 0.5mg 1mg N=185 N=188 N=184 N=179 n(%)[events] n(%)[events] n(%)[events] n(%)[events] n(%)[events] AnyAE 94(52)[185] 91 Anydrug-related AE 27(15)[40] 26

Citation complémentaire (valeur)

(49)[192] 95(51)[201] 100 (54)[217] 94(53)[189] (14)[48] 39(21)[52] 30(16)[41] 35(20)[48]

Gubelin Harcha W, Barboza Martínez J, Tsai TF et al.. A randomized, active- and placebo-controlled study of the efficacy and safety of different doses of dutasteride versus placebo and finasteride in the treatment of male subjects with androgenetic alopecia.. J Am Acad Dermatol 2014, DOI 10.1016/j.jaad.2013.10.049. Citation reproduite au titre du droit de courte citation (article L122-5 du Code de la propriété intellectuelle).

TableV.Adverseevents,includingcommonadverseeventsreportedpostrandomizationbytreatmentgroup Placebo N=181 Dutasteride Finasteride 0.02mg 0.1mg 0.5mg 1mg N=185 N=188 N=184 N=179 n(%)[events] n(%)[events] n(%)[events] n(%)[events] n(%)[events] AnyAE 94(52)[185] 91 Anydrug-related AE 27(15)[40] 26 AnySAE* 2(1) [2] Death 0 CommonAEs ($3% inany group) Nasopharyngitis 16(9) 19 Decreased libido 2(1) 10

Citation complémentaire (valeur)

(49)[192] 95(51)[201] 100 (54)[217] 94(53)[189] (14)[48] 39(21)[52] 30(16)[41] 35(20)[48] 0 3 (2)[4] 1 (\1)[3] 2 (1)[4] 0 0 0 0 (10) 15(8) 23(13) 14(8) (5) 9 (5) 6 (3) 9 (5)

Gubelin Harcha W, Barboza Martínez J, Tsai TF et al.. A randomized, active- and placebo-controlled study of the efficacy and safety of different doses of dutasteride versus placebo and finasteride in the treatment of male subjects with androgenetic alopecia.. J Am Acad Dermatol 2014, DOI 10.1016/j.jaad.2013.10.049. Citation reproduite au titre du droit de courte citation (article L122-5 du Code de la propriété intellectuelle).

TableV.Adverseevents,includingcommonadverseeventsreportedpostrandomizationbytreatmentgroup Placebo N=181 Dutasteride Finasteride 0.02mg 0.1mg 0.5mg 1mg N=185 N=188 N=184 N=179 n(%)[events] n(%)[events] n(%)[events] n(%)[events] n(%)[events] AnyAE 94(52)[185] 91 Anydrug-related AE 27(15)[40] 26 AnySAE* 2(1) [2] Death 0 CommonAEs ($3% inany group) Nasopharyngitis 16(9) 19 Decreased libido 2(1) 10

Citation complémentaire (valeur)

(49)[192] 95(51)[201] 100 (54)[217] 94(53)[189] (14)[48] 39(21)[52] 30(16)[41] 35(20)[48] 0 3 (2)[4] 1 (\1)[3] 2 (1)[4] 0 0 0 0 (10) 15(8) 23(13) 14(8) (5) 9 (5) 6 (3) 9 (5)

Gubelin Harcha W, Barboza Martínez J, Tsai TF et al.. A randomized, active- and placebo-controlled study of the efficacy and safety of different doses of dutasteride versus placebo and finasteride in the treatment of male subjects with androgenetic alopecia.. J Am Acad Dermatol 2014, DOI 10.1016/j.jaad.2013.10.049. Citation reproduite au titre du droit de courte citation (article L122-5 du Code de la propriété intellectuelle).

TableV.Adverseevents,includingcommonadverseeventsreportedpostrandomizationbytreatmentgroup Placebo N=181 Dutasteride Finasteride 0.02mg 0.1mg 0.5mg 1mg N=185 N=188 N=184 N=179 n(%)[events] n(%)[events] n(%)[events] n(%)[events] n(%)[events] AnyAE 94(52)[185] 91 Anydrug-related AE 27(15)[40] 26 AnySAE* 2(1) [2] Death 0 CommonAEs ($3% inany group) Nasopharyngitis 16(9) 19 Decreased libido 2(1) 10 Headache 16(9) 8 Erectiledysfunction 7(4) 8

Citation complémentaire (valeur)

(49)[192] 95(51)[201] 100 (54)[217] 94(53)[189] (14)[48] 39(21)[52] 30(16)[41] 35(20)[48] 0 3 (2)[4] 1 (\1)[3] 2 (1)[4] 0 0 0 0 (10) 15(8) 23(13) 14(8) (5) 9 (5) 6 (3) 9 (5) (4) 8 (4) 11(6) 5 (3) (4) 7 (4) 10(5) 10(6)

Gubelin Harcha W, Barboza Martínez J, Tsai TF et al.. A randomized, active- and placebo-controlled study of the efficacy and safety of different doses of dutasteride versus placebo and finasteride in the treatment of male subjects with androgenetic alopecia.. J Am Acad Dermatol 2014, DOI 10.1016/j.jaad.2013.10.049. Citation reproduite au titre du droit de courte citation (article L122-5 du Code de la propriété intellectuelle).

TableV.Adverseevents,includingcommonadverseeventsreportedpostrandomizationbytreatmentgroup Placebo N=181 Dutasteride Finasteride 0.02mg 0.1mg 0.5mg 1mg N=185 N=188 N=184 N=179 n(%)[events] n(%)[events] n(%)[events] n(%)[events] n(%)[events] AnyAE 94(52)[185] 91 Anydrug-related AE 27(15)[40] 26 AnySAE* 2(1) [2] Death 0 CommonAEs ($3% inany group) Nasopharyngitis 16(9) 19 Decreased libido 2(1) 10 Headache 16(9) 8 Erectiledysfunction 7(4) 8

Citation complémentaire (valeur)

(49)[192] 95(51)[201] 100 (54)[217] 94(53)[189] (14)[48] 39(21)[52] 30(16)[41] 35(20)[48] 0 3 (2)[4] 1 (\1)[3] 2 (1)[4] 0 0 0 0 (10) 15(8) 23(13) 14(8) (5) 9 (5) 6 (3) 9 (5) (4) 8 (4) 11(6) 5 (3) (4) 7 (4) 10(5) 10(6)

Gubelin Harcha W, Barboza Martínez J, Tsai TF et al.. A randomized, active- and placebo-controlled study of the efficacy and safety of different doses of dutasteride versus placebo and finasteride in the treatment of male subjects with androgenetic alopecia.. J Am Acad Dermatol 2014, DOI 10.1016/j.jaad.2013.10.049. Citation reproduite au titre du droit de courte citation (article L122-5 du Code de la propriété intellectuelle).